AR plays a pivotal role in the development and progression of localized and metastatic prostate cancer.[1] Despite advancements in medical treatment, prostate cancer remains the second leading cause of cancer‐related deaths among men in the United States and the fifth leading cause of cancer‐related deaths worldwide.[2, 3] In addition to surgery and radiotherapy, androgen deprivation therapy (ADT) is the first‐line treatment for patients with prostate cancer, to reduce hormone levels in the tumors. The gene discussed is AR; the disease is Familial prostate cancer.